Innovation in targeted therapies: Leading companies in photodynamic cancer therapy drugs

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Targeted therapies in Pharmaceuticals: Photodynamic cancer therapy drugs.

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Premium Insights Targeted therapies in Pharmaceuticals: Photodynamic cancer therapy drugs

Buy the Report

Related Company Profiles

Merck KGaA

Vertex Pharmaceuticals Inc

PDT, Inc.

Massachusetts General Hospital

GlycoMira Therapeutics Inc

View all

Photodynamic cancer therapy drugs is a key innovation area in targeted therapies

Photodynamic therapy (PDT) is a class of therapy that uses light (photosensitising agent) to activate the drug (photosensitiser) to destroy cancer cells. PDT is highly precise and is used to target the cancer cells without affecting the normal cells. The drug is activated only on the cancer cells by using certain kinds of lasers,light-emitting diodes (LEDs), or radiation. It does not cause scarring, which makes it a good alternative to surgery.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of photodynamic cancer therapy drugs.

Key players in photodynamic cancer therapy drugs  

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to photodynamic cancer therapy drugs

Nanobiotix is one of the leading patent filers in photodynamic cancer therapy drugs. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment. The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy..

In terms of application diversity, Merck is the top company, followed by GlycoMira Therapeutics and Vertex Pharmaceuticals. By means of geographic reach, Lunella Biotech holds the top position. Massachusetts General Hospital and Calidi Biotherapeutics are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.

Share this article